Ausgewählte Publikationen der Arbeitsgruppe

  • Braumann, C., Buchholz, M., Stiller, B. M., Hahn, S., Uhl, W., Kasi, A., & Mueller, D. T. (2020). Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study. Journal of Clinical Oncology, 38(15_suppl), e16750-e16750.
  • Buchholz, M., Majchrzak-Stiller, B., Hahn, S., Vangala, D., Pfirrmann, R. W., Uhl, W., Braumann, C., & Chromik, A. M. (2017). Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo. BMC Cancer, 17(1), 216.
  • Majchrzak, B., Buchholz, M., Hahn, S., Braumann, C., & Uhl, W. (2020). Pancreatic Tumor Remission in PDX-Models By Treatment with Gemcitabine in Combination with The Oxathiazine GP-2250. Oncology Research and Treatment, 43, 1-265.
  • Höhn, P., Buchholz, M., Majchrzak, B., Uhl, W., Braumann, C., & Chromik, A. M. (2017). The Physiological Incubation Biosimulator (PIBS): An Improved Ex Vivo Experimental Setup for the Mechanical Stability of Biological Sealants in Surgical Procedures. Surg Innov, 24(3), 214-222.